Skip to main
PMN

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences is a promising clinical-stage biotechnology company with a differentiated monoclonal antibody, PMN310, designed to selectively target toxic, misfolded amyloid-beta oligomers in early Alzheimer's disease (AD). If proven effective, the drug has the potential to overcome safety hurdles and directly compete with established players. The upcoming 12-month data in the PRECISE-AD Phase 1b study will provide a comprehensive assessment of the drug's safety, biomarker, and clinical outcomes, and any observed efficacy with low risks of ARIA would support its potential for uptake. The addition of predictive biomarkers and FDA engagement in the future highlights the company's commitment and potential for success in the AD market.

Bears say

ProMIS Neurosciences is a clinical-stage biotechnology company with a potential for growth, driven by its product candidate PMN310, which is currently in Phase Ib study for treatment of Alzheimer's disease. However, challenges regarding efficacy and potential safety issues could hinder the company's success, along with the need for financing. Additionally, there is competition in the market as well as risks associated with regulatory approval.

PMN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 4 analysts, PMN has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.